Garmin Sued Over BIA Body Composition Accuracy Claims in USA

Garmin is facing a proposed class action lawsuit in the United States over allegedly misleading accuracy claims tied to its BIA (bioelectrical impedance analysis) body composition features, specifically targeting the Index S2 smart scale. This isn't a minor complaint about rounding errors. The suit alleges that Garmin overstated the precision of metrics like body fat percentage, muscle mass, and bone mass to a degree that misled consumers into purchasing a product that couldn't deliver what was advertised.

What BIA Actually Measures

BIA works by sending a weak electrical current through the body and measuring resistance. From that resistance, it estimates body composition using population-based formulas. The key word is estimates. No consumer BIA device, including Garmin's Index S2, Withings Body Comp, or any Tanita scale, produces clinical-grade body fat readings. Research consistently shows BIA consumer devices carry a margin of error of roughly 3 to 5 percentage points compared to DEXA scans, the gold standard. If Garmin's marketing implied laboratory-level accuracy, that's where the legal exposure sits. The lawsuit reportedly hinges on specific language used in product listings and packaging rather than on whether BIA itself is a flawed technology.

It's worth separating the sensor physics here too. BIA is electrical impedance, not optical. Wrist-based optical PPG sensors on watches like the Fenix 8 or Forerunner 965 measure blood volume changes via light to estimate heart rate. The Index S2 uses a completely different signal pathway running current through your feet via the scale's electrodes. Confusing the two is easy but wrong, and it matters for understanding what the lawsuit is actually targeting.

The Index S2 in Context

The Index S2 retails around $149.99 and competes directly with the Withings Body+ ($99) and the Withings Body Comp ($199). Garmin's scale syncs seamlessly with Connect IQ, tracks weight, BMI, body fat, skeletal muscle mass, bone mass, and body water percentage. For a triathlete or Hyrox athlete tracking long-term body composition trends across a training block, that ecosystem integration is genuinely useful. The problem isn't trend tracking, where relative changes matter more than absolute accuracy. The problem is if someone believed the absolute numbers were clinically precise.

For comparison, Withings has always been careful to frame its body composition readings as estimates and to note variability factors like hydration status, time of day, and recent exercise. Polar doesn't sell a connected scale but integrates with third-party options. Garmin's Connect app does display body composition data with a level of visual polish that could imply more confidence in the numbers than the underlying science supports. Whether that crosses a legal threshold is what the court will decide.

What Athletes Should Know Right Now

If you own an Index S2 and use it for weekly trend data, keep using it. A consistent measurement protocol (same time of day, fasted, post-void) makes relative changes meaningful even if the absolute body fat percentage is off by 3 to 4 points. A cyclist dropping from 18% to 14% body fat over a 16-week build is real signal even if the true values are 15% and 11%. That's how most sports dietitians recommend using consumer BIA anyway. What you should not do is use the Index S2 numbers to make clinical decisions about metabolic health or compare your reading directly against a DEXA result and expect them to match.

Garmin has not recalled the Index S2 and has not publicly acknowledged any inaccuracy beyond what's standard for BIA technology. The company's legal team will almost certainly argue that accuracy disclaimers exist in the product documentation and that body composition estimates are industry-standard language across all BIA consumer devices. That defense has legs. Class actions against consumer electronics companies over accuracy claims are notoriously hard to win at scale, and settlements, if they happen, tend to be modest. This case mirrors earlier suits against Fitbit over optical heart rate accuracy, which settled without major product changes.

What's disappointing here isn't really the lawsuit itself, it's that this conversation needs to happen at all in 2026. Every major wearable brand, including Garmin, Polar, Whoop, and Apple, continues to market health metrics with a confidence that the underlying sensor technology doesn't always justify. Whoop's HRV and recovery scores, Garmin's Body Battery, Apple Watch's atrial fibrillation detection (which is genuinely validated) all sit on a spectrum of clinical validity that consumers rarely get a straight answer about. If this case forces clearer labeling on BIA products across the board, that's a net positive for athletes trying to make informed decisions. You can see how Garmin's broader feature ecosystem is evolving in the [Q2 2026 feature update](/en/articles/garmin-q2-2026-update-six-new-watch-features-reviewed-2026-06-14), and it's worth noting that [Garmin and Coros owners are already among the most likely to consider switching brands in 2026](/en/articles/garmin-and-coros-owners-most-likely-to-switch-brands-in-2026-2026-06-09), so reputational pressure from cases like this isn't trivial.

The verdict here depends entirely on what Garmin's actual marketing copy said and whether a reasonable consumer would interpret it as a clinical accuracy claim. The Index S2 is a solid connected scale for trend tracking. It is not a DEXA machine. If Garmin implied otherwise in its advertising, they have a problem. If they used standard BIA industry language and the plaintiffs are overstretching, the case likely collapses or settles for nuisance value. For athletes in the market for a smart scale right now, the Withings Body Comp at $199 offers similar BIA metrics with stronger third-party integrations and a company with a longer track record of conservative accuracy language. The Index S2 remains a reasonable buy if you're already in the Garmin ecosystem and understand what BIA can and can't tell you.